Barcelona-area biomedical research institute specializing in cancer biology, vascular stem cells, iPSC disease modeling, and 3D tissue engineering.
IDIBELL is a biomedical research foundation based near Barcelona, focused on cancer biology, vascular biology, and regenerative medicine. Their core work spans understanding tumor mechanisms — from metastasis and dormancy to cancer stem cells — and translating molecular discoveries into diagnostic and therapeutic tools. They also develop iPSC-based platforms for disease modeling and have growing expertise in tissue engineering, including 3D bioprinting of vascular grafts and cardiac tissue. Several of their projects bridge oncology with cardiology, addressing chemotherapy-induced heart damage and cardioprotection strategies.
Dominant theme across projects including EPICUP, EPIPHARM (cancer diagnostics via DNA methylation), META-CAN (cancer metabolism), Evomet (metastasis evolution), PLEIO-RANK (cancer stem cells), and Organ-VIP (colorectal cancer organoids).
PI3K-VAs studied vascular anomalies and angiogenesis signaling; ReSinAge focuses on vascular endothelial stem cell niches; STEMCEDIF and PhyCaR involve vascular tissue engineering and cardiac regeneration.
ReSinAge (hematopoietic stem cell niches), PhyCaR (cardiac regeneration with iPSCs and bioprinting), STEMCEDIF (stem cell-laden vascular grafts), NEUROSTAD (stem cells in neurogenesis), and scGATA2track (iPSC-based disease modeling).
EPICUP and EPIPHARM developed ncRNA DNA methylation kits for cancer of unknown primary diagnosis and treatment guidance; MEsHH studied DNA methylation for HPV-related disease.
NeurAntigen built a human neural platform from iPSCs for autoimmune encephalitis diagnostics; scGATA2track uses hiPSCs for tracking malignant transformation; PhyCaR and STEMCEDIF use iPSC-derived cells for tissue engineering.
RESILIENCE investigates cardiac protection during anthracycline chemotherapy; PhyCaR explores pseudohypoxia-mediated cardiac regeneration — together representing a new research axis connecting oncology and cardiology.
In the early period (2015–2018), IDIBELL focused on fundamental cancer biology — ER stress pathways, PI3K signaling, breast cancer immunology, and epigenetic diagnostics for cancers of unknown primary. From 2019 onward, a clear shift emerges toward translational and regenerative applications: organoid-based genetic variant interpretation, iPSC-derived disease models (for autoimmune encephalitis, cardiac regeneration), 3D bioprinting, and vascular tissue engineering. There is also a notable expansion into cardio-oncology, studying how to protect the heart from cancer treatment damage — a field that bridges their oncology roots with regenerative medicine ambitions.
IDIBELL is moving from understanding cancer at the molecular level toward building functional tissue models and regenerative therapies, with iPSC technology and 3D bioprinting as enabling platforms — making them an increasingly attractive partner for translational and tissue engineering consortia.
IDIBELL overwhelmingly leads its projects: 18 of 24 projects were coordinated by them, predominantly individual Marie Skłodowska-Curie fellowships and ERC Proof of Concept grants. This reflects an organization that attracts top-tier researchers who bring their own funding rather than one that primarily joins large consortia. With 97 unique partners across 21 countries, they maintain a broad but relatively shallow network — many one-time collaborations through training networks rather than deep repeated partnerships.
IDIBELL has worked with 97 distinct partners across 21 countries, reflecting broad European reach. The network is built largely through MSCA training networks and individual fellowships, suggesting connections spread across many institutions rather than concentrated in a few key alliances.
IDIBELL stands out as a cancer-focused research institute that has successfully pivoted toward regenerative medicine and tissue engineering without abandoning its oncology core. Their emerging cardio-oncology work — protecting hearts from cancer treatment damage — sits at an unusual and high-demand intersection that few European research centers occupy. Their strong track record of hosting MSCA fellows (10+ fellowships) signals an institution that consistently attracts international talent and provides a productive research environment.
